The Need for Presurgical Evaluation for Placenta Accreta Spectrum

Abstract

Staging or grading of placenta accreta spectrum has historically relied on histopathologic evaluation of placental and uterine specimens. This approach has limited utility, since it is retrospective in nature and does not allow for presurgical planning. Here, we argue for a paradigm shift to use of clinical and imaging characteristics to define the presurgical stage. We summarize past attempts at staging, and define a new data-driven approach to determining the stage prior to delivery. Use of this model may help hospitals direct patients to the most appropriate level of care for workup and management of placenta accreta spectrum.

Key Points

• Staging systems that rely on histopathologic grade (accreta, increta, percreta) are unhelpful in antenatal planning for placenta accreta spectrum.

• Past attempts at pre-delivery (pre-surgical) staging have failed to account for key factors that contribute to risk and morbidity.

• We developed a data-driven model that could be easily incorporated as a decision aid into clinical practice to help clinicians decide an individual patient's risk for placenta accreta spectrum.

Keywords

prenatal ultrasound - risk assessment - hemorrhage - levels of maternal care - hysterectomy

Publication History

Article published online:
19 June 2023

• References

• 1 Forster DS. A case of placenta accreta. Can Med Assoc J 1927; 17 (02) 204-207
• 2 Odicino F, Pecorelli S, Zigliani L, Creasman WT. History of the FIGO cancer staging system. Int J Gynaecol Obstet 2008; 101 (02) 205-210
• 3 Clark HR, Ng TW, Khan A. et al. Placenta accreta spectrum: correlation of MRI parameters with pathologic and surgical outcomes of high-risk pregnancies. AJR Am J Roentgenol 2020; 214 (06) 1417-1423
• 4 Cali G, Timor-Tritsch I, Forlani F. et al. Integration of first-trimester assessment in the ultrasound staging of placenta accreta spectrum disorders. Ultrasound Obstet Gynecol 2019
• 5 Cali G, Forlani F, Lees C. et al. Prenatal ultrasound staging system for placenta accreta spectrum disorders. Ultrasound Obstet Gynecol 2019; 53 (06) 752-760
• 6 Knight JC, Lehnert S, Shanks AL. et al. A comprehensive severity score for the morbidly adherent placenta: combining ultrasound and magnetic resonance imaging. Pediatr Radiol 2018; 48 (13) 1945-1954
• 7 Maymon R, Melcer Y, Pekar-Zlotin M, Shaked O, Cuckle H, Tovbin J. Bedside risk estimation of morbidly adherent placenta using simple calculator. Arch Gynecol Obstet 2018; 297 (03) 631-635
• 8 Tovbin J, Melcer Y, Shor S. et al. Prediction of morbidly adherent placenta using a scoring system. Ultrasound Obstet Gynecol 2016; 48 (04) 504-510
• 9 Ueno Y, Maeda T, Tanaka U. et al. Evaluation of interobserver variability and diagnostic performance of developed MRI-based radiological scoring system for invasive placenta previa. J Magn Reson Imaging 2016; 44 (03) 573-583
• 10 Rac MW, Dashe JS, Wells CE, Moschos E, McIntire DD, Twickler DM. Ultrasound predictors of placental invasion: the Placenta Accreta Index. Am J Obstet Gynecol 2015; 212 (03) 343.e1-343.e7
• 11 Weiniger CF, Einav S, Deutsch L, Ginosar Y, Ezra Y, Eid L. Outcomes of prospectively-collected consecutive cases of antenatal-suspected placenta accreta. Int J Obstet Anesth 2013; 22 (04) 273-279
• 12 Palacios Jaraquemada JM, Bruno CH. Magnetic resonance imaging in 300 cases of placenta accreta: surgical correlation of new findings. Acta Obstet Gynecol Scand 2005; 84 (08) 716-724
• 13 Bourgioti C, Zafeiropoulou K, Fotopoulos S. et al. MRI features predictive of invasive placenta with extrauterine spread in high-risk gravid patients: a prospective evaluation. AJR Am J Roentgenol 2018; 211 (03) 701-711
• 14 Calì G, Giambanco L, Puccio G, Forlani F. Morbidly adherent placenta: evaluation of ultrasound diagnostic criteria and differentiation of placenta accreta from percreta. Ultrasound Obstet Gynecol 2013; 41 (04) 406-412
• 15 Creanga AA, Bateman BT, Butwick AJ. et al. Morbidity associated with cesarean delivery in the United States: is placenta accreta an increasingly important contributor?. Am J Obstet Gynecol 2015; 213 (03) 384.e1-384.e11
• 16 Clark SL, Koonings PP, Phelan JP. Placenta previa/accreta and prior cesarean section. Obstet Gynecol 1985; 66 (01) 89-92
• 17 Miller DA, Chollet JA, Goodwin TM. Clinical risk factors for placenta previa-placenta accreta. Am J Obstet Gynecol 1997; 177 (01) 210-214
• 18 Silver RM, Landon MB, Rouse DJ. et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107 (06) 1226-1232
• 19 Marshall NE, Fu R, Guise JM. Impact of multiple cesarean deliveries on maternal morbidity: a systematic review. Am J Obstet Gynecol 2011; 205 (03) 262.e1-262.e8
• 20 Bailit JL, Grobman WA, Rice MM. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol 2015; 125 (03) 683-689
• 21 Thurn L, Lindqvist PG, Jakobsson M. et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG 2016; 123 (08) 1348-1355
• 22 Carusi DA, Fox KA, Lyell DJ, Perlman NC, Aalipour S, Einerson BD, Belfort MA, Silver RM, Shamshirsaz AA. Placenta Accreta Spectrum Without Placenta Previa. Obstet Gynecol 2020; Sep; 136 (03) 458-465
• 23 Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. Incidence and risk factors for placenta accreta/increta/percreta in the UK: a national case-control study. PLoS One 2012; 7 (12) e52893
• 24 Hung TH, Shau WY, Hsieh CC, Chiu TH, Hsu JJ, Hsieh TT. Risk factors for placenta accreta. Obstet Gynecol 1999; 93 (04) 545-550
• 25 Farquhar CM, Li Z, Lensen S. et al. Incidence, risk factors and perinatal outcomes for placenta accreta in Australia and New Zealand: a case-control study. BMJ Open 2017; 7 (10) e017713
• 26 Bowman ZS, Eller AG, Bardsley TR, Greene T, Varner MW, Silver RM. Risk factors for placenta accreta: a large prospective cohort. Am J Perinatol 2014; 31 (09) 799-804
• 27 Baldwin HJ, Patterson JA, Nippita TA. et al. Antecedents of abnormally invasive placenta in primiparous women: risk associated with gynecologic procedures. Obstet Gynecol 2018; 131 (02) 227-233
• 28 Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol 2018; 218 (01) 75-87
• 29 Salmanian B, Fox KA, Arian SE. et al. In vitro fertilization as an independent risk factor for placenta accreta spectrum. Am J Obstet Gynecol 2020; 223 (04) 568.e1-568.e5
• 30 Modest AM, Toth TL, Johnson KM, Shainker SA. Placenta accreta spectrum: in vitro fertilization and non-in vitro fertilization and placenta accreta spectrum in a Massachusetts cohort. Am J Perinatol 2021; 38 (14) 1533-1539
• 31 Bauer AM, Hackney DN, El-Nashar S, Sheyn D. Pregnancy outcomes after endometrial ablation in a multi-institutional cohort. Am J Perinatol 2018; 35 (10) 931-935
• 32 Kohn JR, Shamshirsaz AA, Popek E, Guan X, Belfort MA, Fox KA. Pregnancy after endometrial ablation: a systematic review. BJOG 2018; 125 (01) 43-53
• 33 Sentilhes L, Ambroselli C, Kayem G. et al. Maternal outcome after conservative treatment of placenta accreta. Obstet Gynecol 2010; 115 (03) 526-534
• 34 Miller ES, Linn RL, Ernst LM. Does the presence of placental basal plate myometrial fibres increase the risk of subsequent morbidly adherent placenta: a case-control study. BJOG 2016; 123 (13) 2140-2145
• 35 Zelop C, Nadel A, Frigoletto Jr FD, Pauker S, MacMillan M, Benacerraf BR. Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein. Obstet Gynecol 1992; 80 (04) 693-694
• 36 Kupferminc MJ, Tamura RK, Wigton TR, Glassenberg R, Socol ML. Placenta accreta is associated with elevated maternal serum alpha-fetoprotein. Obstet Gynecol 1993; 82 (02) 266-269
• 37 Lyell DJ, Faucett AM, Baer RJ. et al. Maternal serum markers, characteristics and morbidly adherent placenta in women with previa. J Perinatol 2015; 35 (08) 570-574
• 38 Einerson BD, Straubhar A, Soisson S. et al. Hyperglycosylated hCG and placenta accreta spectrum. Am J Perinatol 2019; 36 (01) 22-26
• 39 Shainker SA, Silver RM, Modest AM. et al. Placenta accreta spectrum: biomarker discovery using plasma proteomics. Am J Obstet Gynecol 2020; 223 (03) 433.e1-433.e14
• 40 Twickler DM, Lucas MJ, Balis AB. et al. Color flow mapping for myometrial invasion in women with a prior cesarean delivery. J Matern Fetal Med 2000; 9 (06) 330-335
• 41 Shih JC, Palacios Jaraquemada JM, Su YN. et al. Role of three-dimensional power Doppler in the antenatal diagnosis of placenta accreta: comparison with gray-scale and color Doppler techniques. Ultrasound Obstet Gynecol 2009; 33 (02) 193-203
• 42 Wong HS, Cheung YK, Zuccollo J, Tait J, Pringle KC. Evaluation of sonographic diagnostic criteria for placenta accreta. J Clin Ultrasound 2008; 36 (09) 551-559
• 43 D'Antonio F, Iacovella C, Bhide A. Prenatal identification of invasive placentation using ultrasound: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2013; 42 (05) 509-517
• 44 D'Antonio F, Iacovella C, Palacios-Jaraquemada J, Bruno CH, Manzoli L, Bhide A. Prenatal identification of invasive placentation using magnetic resonance imaging: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2014; 44 (01) 8-16